{
  "catalysts": [
    {
      "ticker": "AXSM",
      "current_price": 94.5,
      "market_cap": "$4.5B",
      "conviction_score": 9,
      "thesis": "Positive Pre-NDA meeting minutes for AXS-12 (Narcolepsy) released on Dec 31 de-risk the imminent January 2026 filing. The market has not reacted due to the New Year's holiday.",
      "catalyst_details": "NDA Submission for AXS-12 expected January 2026; Pre-NDA agreement confirmed Dec 31, 2025.",
      "absorption_status": "News broke Dec 31 (New Year's Eve) amidst holiday low volume; markets closed Jan 1, leaving the catalyst completely unpriced.",
      "earnings_date": "Late Feb 2026",
      "relative_volume": "0.4x 30d avg (Holiday Thin)",
      "stop_loss_trigger": "Close below $88.00 (Trend support)",
      "sentiment": "Bullish",
      "prediction_market": "N/A",
      "recency_proof": "BioSpace Dec 31, 2025: AXSM confirms Pre-NDA agreement",
      "risk": "Unexpected delay in actual January filing submission.",
      "expected_upside": "10-15% drift on volume return",
      "mispricing_evidence": "Zero price reaction to material regulatory progress due to holiday timing.",
      "x_sentiment": "Low chatter (Holiday silence)"
    },
    {
      "ticker": "ASND",
      "current_price": 138.4,
      "market_cap": "$7.8B",
      "conviction_score": 7,
      "thesis": "TransCon CNP (Achondroplasia) PDUFA in Feb 2026. Stock has drifted since Nov 2025 delay, offering a discounted entry ahead of the final decision.",
      "catalyst_details": "FDA PDUFA Date: February 28, 2026 (TransCon CNP).",
      "absorption_status": "Overshadowed by the 3-month review extension announced in Nov; price has stabilized but not run up yet.",
      "earnings_date": "Feb 2026",
      "relative_volume": "1.0x 30d avg",
      "stop_loss_trigger": "Close below $125",
      "sentiment": "Bullish",
      "prediction_market": "N/A",
      "recency_proof": "HCPLive Dec 24, 2025: Confirms Feb 28 PDUFA",
      "risk": "Further delays or CRL.",
      "expected_upside": "15-20% run-up into Feb",
      "mispricing_evidence": "Flat price action despite approaching blockbuster approval date.",
      "x_sentiment": "Quiet accumulation"
    }
  ]
}